GOSS News and Press, Gossamer Bio Inc. From 03/07/23

2023-03-07 12:08:06 ET Merck’s ( MRK ) newly published full Phase 3 data for sotatercept in pulmonary arterial hypertension (PAH) has led Raymond James to downgrade the rival PAH drug developer Gossamer Bio ( NASDAQ: GOSS ) to Market Perform from Outperform on T...

Gossamer Bio ( NASDAQ: GOSS ) lost ~6% Wednesday after Guggenheim initiated its coverage with a Neutral rating, citing a challenging commercial outlook for the company's tyrosine kinase inhibitor (TKI) seralutinib targeted at pulmonary arterial hypertension (PAH). While noting tha...

Summary Last year, Gossamer Bio failed its ulcerative colitis trial. Then, in late 2022, GOSS met the primary endpoint in the PAH trial, but overall, the trial was a failure. There is nothing further ahead for the company right now, although they will do a phase 3 trial in PAH. ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While everyone knows that in order to have a market, there must be bulls and bears, that’s not going to stop people from attempting to garner intense profits from top short-squeeze candidates. To quickly summarize, sho...

This week could bring some fluctuations to the stock market. Whether you’re investing in penny stocks or more expensive shares, several key factors will shape the year’s first quarter. Economic data releases, earnings announcements, and the highly anticipated January FOMC meeting ar...

Summary Gossamer's TORREY showed stat sig PVR improvement, but the 6MWD was under what investors were hoping for; this led to a +70% decline in share price. Seralutnib is entering phase 3 with an adapted design (with more severe patients); although the success is less clear, any positiv...

Summary Aerovate is a SMID-cap biotech developing an inhaled imatinib for pulmonary arterial hypertension. AV-101's Phase 2b PAH data is expected in 4Q 2023 or 1Q 2024, which we believe will be positive. We believe the data will be positive based on imatinib's robust efficacy data (...

Are These Penny Stocks In For A Short Squeeze? Penny stocks are shares of companies that trade for less than $5 per share. They also tend to represent smaller companies. Their higher risk/higher reward makeup generally makes them a hot topic for retail traders. Any given day might see low-pri...

Thanks to the stock market crash this year, plenty of penny stocks are trading at significantly lower prices. That has brought about the topic of shorting stocks. If you don’t trade options, shorting can present opportunities to make money when stocks drop. Shorting can also create a scena...

Short Squeeze Penny Stocks To Watch Today You’ve got your strategy laid out, you know you want to make money with penny stocks ; now what? It might seem as easy as throwing a dart at a dart board at times. But 2022 has been one of the more challenging years to trade like that. ...